GALANTAMINE ER CAPSULE (EXTENDED RELEASE)
Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
Ciri produk
(SPC)
23-06-2017
Beberapa dokumen untuk produk ini saat ini tidak tersedia, anda dapat mengirim permintaan ke layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami dapat memperolehnya.
Hantar permintaan.
Hantar permintaan.
Bahan aktif:
GALANTAMINE (GALANTAMINE HYDROBROMIDE)
Boleh didapati daripada:
SANIS HEALTH INC
Kod ATC:
N06DA04
INN (Nama Antarabangsa):
GALANTAMINE
Dos:
16MG
Borang farmaseutikal:
CAPSULE (EXTENDED RELEASE)
Komposisi:
GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16MG
Laluan pentadbiran:
ORAL
Unit dalam pakej:
100
Jenis preskripsi:
Prescription
Kawasan terapeutik:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Ringkasan produk:
Active ingredient group (AIG) number: 0144660004; AHFS:
Status kebenaran:
APPROVED
Tarikh kebenaran:
2016-01-07
Ciri produk
Page 1 of 55
PRODUCT MONOGRAPH
PR
GALANTAMINE ER
Galantamine Hydrobromide Extended-Release Capsules
8 mg, 16 mg, 24 mg galantamine base
Cholinesterase Inhibitor
SANIS HEALTH INC.
1 President's Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Revision: June 22, 2017
Submission Control No: 206599
Page 2 of 55
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND STABILITY
.........................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.........................................................................
25
CLINICAL TRIALS
.........................................................................................................
26
DETAILED PHARMACOLOGY
..............................................
Baca dokumen lengkap
